Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
10 9월 2024 - 12:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 9, 2024
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 9 September
2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No
596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March
2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed
during a 12-month period beginning 6 February 2024.
Under the programme initiated 7 August 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from
7 August 2024 to 4 November 2024.
Since 2 September 2024, the following transactions have been made:
| |
Number
of B
shares |
Average
purchase
price |
Transaction
value,
DKK |
| Accumulated,
last announcement |
744,187 |
|
671,844,599 |
| 2
September 2024 |
45,000 |
925.37 |
41,641,843 |
| 3
September 2024 |
41,000 |
933.58 |
38,276,681 |
| 4
September 2024 |
43,000 |
905.99 |
38,957,720 |
| 5
September 2024 |
41,000 |
893.85 |
36,648,039 |
| 6 September
2024 |
42,000 |
885.28 |
37,181,588 |
| Accumulated
under the programme |
956,187 |
|
864,550,471 |
The details for each transaction made under the share repurchase programme are published on
novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 13,351,944 B shares of DKK 0.10 as treasury shares, corresponding to
0.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As
of 6 September 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 12,023,313 B shares at an average share price of DKK
880.98 per B share equal to a transaction value of DKK 10,592,256,521.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contact for further information.
| Media: |
|
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
| |
|
| Investors: |
|
|
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
| |
|
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
| |
|
|
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com
CVR no: 24 25 67 90 |
| | | | Company
announcement No 69 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: September 9, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Novo Nordisk (PK) (USOTC:NONOF)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
